Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 36Nivolumab 16Cyclophosphamide 12atezolizumab 8Docetaxel 8Magnetic Resonance Spectroscopy 7Paclitaxel 6Everolimus 6spartalizumab 5fludarabine 5durvalumab 5Specimen Handling 5Ipilimumab 5cabozantinib 4avelumab 4Trastuzumab 4Radiotherapy 4Radiosurgery 4Oxaliplatin 4Leucovorin 4temsirolimus 3pazopanib 3aldesleukin 3Taxes 3Sunitinib 3Psychiatric Rehabilitation 3Interleukin-2 3Immune Checkpoint Inhibitors 3Gemcitabine 3Fluorouracil 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × parsaclisib × Breast × Clear all
NCT02646748 2022-03-31

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Incyte Corporation

Phase 1 Completed
159 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡